Melanoma begins with DNA damage in melanocytes, the pigment-producing cells scattered through the outer layer of your skin, and it progresses through a series of biological shifts that let tumor cells grow unchecked, invade surrounding tissue, and eventually colonize distant organs. What makes melanoma particularly dangerous compared to other skin cancers is its capacity for rapid evolution: the tumor rewires its own genetics, metabolism, and relationship with the immune system at each stage of progression. Understanding those stages explains both why early detection matters so much and why advanced melanoma has historically been so difficult to treat.
Where It Starts: UV Damage and the Mutations That Launch a Tumor
Most melanomas trace their origin to ultraviolet radiation. When UV light hits your skin, it damages DNA in a characteristic way, producing specific mutations where one DNA letter (cytosine) gets swapped for another (thymine) at spots where two pyrimidine bases sit side by side. Whole-exome sequencing of hundreds of melanomas has confirmed that more than three-quarters carry this UV mutation signature, accounting for over 60% of the mutations found in the tumor genome. Melanomas from sun-exposed body sites show this signature clearly, while those from sun-shielded areas do not.1PubMed Central. UVA Radiation, DNA Damage, and Melanoma That distinction matters because it points to a real divide in melanoma biology: sun-driven tumors and non-sun-driven tumors often follow different genetic paths.
UV damage alone is not enough. Your body repairs most DNA damage before it causes trouble. Melanoma takes hold when mutations accumulate in genes that control cell growth and survival, overwhelm the repair machinery, and disable the built-in brakes that normally stop a damaged cell from dividing. The most common genetic drivers sort melanomas into four molecular subtypes: BRAF-mutant, NRAS-mutant, NF1-mutant, and triple wild-type tumors (those lacking mutations in any of the first three genes).2PubMed Central. The NF1 gene in tumor syndromes and melanoma About half of all melanomas carry a mutation in the BRAF gene, and over 90% of those are a specific change called V600E. That single mutation locks a signaling pathway into the “on” position, telling cells to keep dividing.3PubMed Central. The role of BRAF V600 mutation in melanoma
Familial risk adds another layer. Some families carry inherited mutations in a gene called CDKN2A, which normally acts as a tumor suppressor. Germline CDKN2A mutations show up in roughly 20% to 40% of melanoma-prone families and are linked to earlier age at diagnosis, multiple primary melanomas in the same person, and an elevated risk of pancreatic cancer.4PubMed Central. Familial Melanoma: Diagnostic and Management Implications
Breaking Free: How Melanoma Cells Start to Invade
A cluster of mutated melanocytes sitting quietly inside the top layer of skin is not yet dangerous. The critical transition happens when those cells lose their normal attachments and begin pushing into deeper tissue. Healthy melanocytes are anchored to surrounding skin cells (keratinocytes) and to the thin structural sheet called the basement membrane. Melanoma cells loosen both of those anchors. They downregulate a sticky surface protein called E-cadherin that normally keeps them tethered to their neighbors, and they disrupt the junctions that hold them to the basement membrane beneath them. Modeling and simulation studies have identified these two losses of adhesion as the fundamental biomechanical triggers for tumor initiation.5PubMed Central. The radial growth phase of malignant melanoma: multi-phase modelling, numerical simulations and linear stability analysis
Once the cells are free to move, they need to physically chew through the dense mesh of proteins (the extracellular matrix) that fills the space between and beneath skin cells. They do this by ramping up production of enzymes called matrix metalloproteinases, or MMPs. These enzymes act like molecular scissors, cutting through the structural scaffold of the matrix and the basement membrane so the melanoma cells can push deeper into the dermis.6PubMed. Role of matrix metalloproteinases in melanoma cell invasion The activity of MMPs and the proteins that keep them in check has become a research focus for potential therapies, since blocking those enzymes could slow or prevent invasion.7PubMed Central. Targeting Matrix Metalloproteinases and Their Inhibitors in Melanoma
Building a Blood Supply
A growing tumor quickly outstrips the oxygen and nutrients available from the surrounding tissue. Without its own blood supply, a melanoma can only grow to about the size of a pinhead. To get past that limit, melanoma cells secrete a protein called VEGF (vascular endothelial growth factor) that signals nearby blood vessels to sprout new branches toward the tumor. Research has shown a strong correlation between VEGF levels and both Breslow depth (how thick the tumor is) and the growth pattern of the melanoma. The thicker and more aggressive the tumor, the more VEGF it produces.8PubMed Central. The role of VEGF in melanoma progression
Standard blood-vessel recruitment sometimes is not enough, especially in low-oxygen zones inside the tumor. Melanoma has a remarkable backup strategy: the cancer cells themselves can form vascular-like channels that carry fluid and mimic real blood vessels, without any help from the endothelial cells that normally line blood vessels. This phenomenon, called vasculogenic mimicry, was first described in aggressive melanoma and has since been recognized in several other cancer types.9PubMed Central. Vasculogenic mimicry and tumor angiogenesis The ability to both recruit conventional blood vessels and build improvised ones gives melanoma a dual supply line, making it harder to starve the tumor by blocking angiogenesis alone.10PubMed Central. Unraveling vascular mechanisms in melanoma: roles of angiogenesis and vasculogenic mimicry in tumor progression and therapeutic resistance
Spreading Through the Lymphatic System
When melanoma does metastasize, the lymphatic system is usually the first highway it takes. Melanoma cells enter the thin-walled lymphatic vessels in the skin and travel to the nearest lymph node, known as the sentinel node. That is why a sentinel lymph node biopsy is a standard part of melanoma staging: finding tumor cells there tells doctors the cancer has started to spread.
Melanoma does not passively stumble into the lymphatic system. Tumor cells secrete a different form of VEGF, called VEGF-C, which causes new lymphatic vessels to sprout and expand inside the sentinel lymph node before tumor cells even arrive there. In animal models, VEGF-C did not make the primary tumor grow faster but significantly remodeled the lymphatic network in the draining node, effectively preparing a welcoming landing pad. Once the lymphatic plumbing in the sentinel node was expanded, the tumor’s ability to spread to more distant sites increased.11PubMed Central. VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites This pre-conditioning of distant tissue is part of a broader phenomenon called premetastatic niche formation, which we will return to shortly.
The Premetastatic Niche: Preparing Distant Organs Before Tumor Cells Arrive
One of the more unsettling discoveries in melanoma biology over the past decade is that tumors send scouts ahead. Even before metastatic cells physically arrive at a distant organ, the primary tumor releases tiny membrane-bound particles called exosomes into the bloodstream. These exosomes carry proteins, RNA, and other molecular cargo that can reprogram the cells in distant tissues. In mouse models, fluorescently labeled exosomes from metastatic melanoma cells exited the bloodstream and concentrated in the organs where melanoma commonly spreads: the lungs, liver, bone marrow, and spleen. Mice that received these exosomes before being implanted with melanoma cells developed significantly more metastatic tumors than controls.12Nature Reviews Cancer. Exosomes drive premetastatic niche formation
The mechanism is not just about opening doors in blood vessel walls. Melanoma-derived exosomes also reprogram the resident cells in those distant tissues. For example, when exposed to melanoma exosomes, fibroblasts in the skin shifted their metabolism, producing acid that altered the local environment in ways that favor tumor-cell survival and growth.13PubMed Central. Metabolic reprogramming of stromal fibroblasts by melanoma exosome microRNA favours a pre-metastatic microenvironment In the case of bone, tumor-derived exosomes activated a specific signaling axis that increased melanoma cells’ attraction to bone tissue.14PubMed Central. Tumor-derived exosomes promote the in vitro osteotropism of melanoma cells by activating the SDF-1/CXCR4/CXCR7 axis The upshot is that metastasis is not random. The primary tumor actively remodels distant organs to make them more hospitable before its cells arrive.
Why Melanoma Prefers Certain Organs
Melanoma metastasizes most often to the skin itself, the lungs, the liver, the brain, and bone. That pattern is not an accident of anatomy or blood flow alone. Melanoma cells display surface receptors that respond to chemical signals produced by specific organs, effectively following a scent trail. Research using mouse melanoma models has mapped several of these receptor-destination pairings: the receptor CCR7 guides cells toward lymph nodes, CXCR4 toward the lungs and liver, and CCR10 back to the skin.15Journal of Dermatological Science. Chemokine receptors and melanoma metastasis
The CXCR4 receptor has drawn particular attention. In patients with melanoma or colorectal cancer that had spread to the liver, CXCR4 expression on the tumor cells correlated with disease outcome. In lab experiments, exposing melanoma cells to CXCL12, the chemical signal that CXCR4 responds to, significantly increased their migration.16PubMed Central. Chemokine Receptor CXCR4 Expression in Patients With Melanoma and Colorectal Cancer Liver Metastases and the Association With Disease Outcome This organ-seeking behavior means that the destination of melanoma metastases is partly written into the biology of the tumor cells themselves.
Surviving the Journey: How Melanoma Cells Avoid Dying in the Bloodstream
Normal cells die when they detach from their home tissue. This built-in self-destruct program is called anoikis, and it is one of the body’s safeguards against rogue cells floating around and setting up camp elsewhere. Melanoma cells evolve ways to override this failsafe. They alter the receptors on their surfaces, particularly integrins like αvβ3, which help them grip new surfaces and receive survival signals even while floating through the bloodstream or lymphatic fluid. Blocking this receptor in mice reduced the number of melanoma colonies forming in the lungs by about 64%.17Frontiers in Cell and Developmental Biology. Therapeutic targeting of anoikis resistance in cutaneous melanoma metastasis
Surviving detachment also requires metabolic flexibility. When melanoma cells are floating free rather than anchored to tissue, they shift their energy supply from the sugar-burning metabolism typical of most cancer cells toward a more oxygen-dependent metabolism that relies on glutamine and fatty acids. Once they re-attach at a distant site, they switch back to their earlier metabolic mode.18PubMed Central. The critical role of glutamine and fatty acids in the metabolic reprogramming of anoikis -resistant melanoma cells This metabolic toggling is part of a broader pattern of adaptability that defines aggressive melanoma.
Dodging the Immune System
Your immune system routinely identifies and destroys abnormal cells, and melanoma has to evade that surveillance to survive. It does so through multiple overlapping strategies. One of the most studied involves a surface protein called PD-L1, which melanoma cells display on their outer membrane. PD-L1 acts like a “stand down” signal to the killer T cells that would otherwise attack the tumor. In melanoma cells that have become resistant to BRAF-targeting drugs, a protein called YAP drives increased PD-L1 expression, enabling the resistant cells to escape immune attack.19Cancer Immunology Research. YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma
The tumor also recruits allies from the immune system itself. Regulatory T cells and myeloid-derived suppressor cells accumulate in and around growing melanomas. These immune cells, which normally prevent your immune system from attacking your own tissues, get co-opted to shield the tumor instead. In mouse melanoma models, myeloid-derived suppressor cells expressed elevated levels of PD-L1 and related inhibitory molecules as tumors grew, and depleting regulatory T cells reversed this effect and slowed tumor growth.20Journal of Investigative Dermatology. Regulatory T Cells Stimulate B7-H1 Expression in Myeloid-Derived Suppressor Cells in ret Melanomas In patients, elevated levels of inflammatory factors in the blood and increased numbers of these suppressive immune cells correlate with more advanced disease and worse prognosis.21PubMed. Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients This understanding is precisely what led to the development of immune checkpoint inhibitors, drugs that block PD-L1 and related proteins to re-awaken the immune response.
Phenotype Switching: Melanoma’s Shape-Shifting Trick
Unlike many cancers that are locked into a single mode of behavior, melanoma cells can flip between different functional states depending on what they need at any given moment. Researchers call this phenotype switching. A melanoma cell might be in a highly proliferative state, dividing rapidly to grow the primary tumor, then shift to a highly invasive state that prioritizes movement over growth. Later, after arriving at a distant organ, it might switch back to the proliferative mode to establish a new colony.22PubMed Central. Phenotype Switching and the Melanoma Microenvironment; Impact on Immunotherapy and Drug Resistance
This switching is not a one-time event but a dynamic, reversible process driven by signals from the tumor’s surrounding environment. It also has major implications for treatment resistance: a drug that targets rapidly dividing cells may miss the ones that have temporarily shifted into a quiescent, invasion-focused state. Those dormant cells can survive therapy and later reactivate, fueling relapse.
Why Targeted Therapy Often Stops Working
Because about half of melanomas carry the BRAF V600E mutation, drugs that specifically block the mutant BRAF protein (called BRAF inhibitors) can produce dramatic initial tumor shrinkage. But roughly 20% of patients never respond at all due to built-in resistance, and among those who do respond, most eventually develop acquired resistance and see their disease progress again.23PubMed Central. Resistant mechanisms to BRAF inhibitors in melanoma
The mechanisms behind this resistance are varied. Some tumors reactivate the same growth-signaling pathway by different means, such as developing secondary mutations or overexpressing certain receptor proteins. Others switch to entirely different signaling pathways to sustain growth, effectively routing around the blocked road. Genetic mutations, changes in gene expression without DNA changes, metabolic rewiring, and remodeling of the tumor’s local environment all contribute.24PubMed Central. BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations This diversity of escape routes is why combination therapies, using a BRAF inhibitor alongside a second drug that blocks a different node in the pathway, have become standard practice. Even so, resistance eventually emerges in many patients, and each cycle of treatment and resistance pushes the tumor’s evolution forward.25Frontiers in Oncology. Diverse Mechanisms of BRAF Inhibitor Resistance in Melanoma Identified in Clinical and Preclinical Studies
Why Thickness Is Not the Whole Story
If you are diagnosed with melanoma, the first thing your pathology report will highlight is Breslow depth, the distance in millimeters from the top of the tumor to its deepest point of invasion. This single measurement is the strongest proven prognostic factor: thicker tumors are more likely to have spread. But the relationship is not absolute. Some thin melanomas metastasize, and some thick melanomas follow a surprisingly favorable course.26PubMed Central. The prognostic significance of the clinical and histological parameters in primary cutaneous melanoma patients That unpredictability is partly explained by the biological features discussed throughout this article: a thin tumor whose cells have already undergone phenotype switching, silenced E-cadherin, activated certain chemokine receptors, or begun seeding exosomes may be more dangerous than its thickness suggests. Conversely, a thick tumor with an active immune infiltrate and limited vascular access may remain localized longer than expected.
Other histological details that pathologists report, such as whether the tumor is ulcerated, how many dividing cells are visible per microscopic field (the mitotic rate), and whether tumor cells have invaded nearby lymphatic or blood vessels, all add information beyond thickness alone. Taken together, these features help explain why two melanomas of the same depth can have very different outcomes.
Acral Melanoma and Other Non-UV-Driven Subtypes
Not all melanomas follow the UV-damage playbook. Acral melanoma, which appears on the palms, soles, and under the nails, is the most common melanoma subtype in people with darker skin and occurs in areas that receive little sun exposure. Its genetic landscape looks markedly different from sun-driven melanoma. Instead of the scattered point mutations characteristic of UV damage, acral melanoma is dominated by a pattern of localized, clustered mutations sometimes described as “hailstorms.” In a cohort of 37 acral melanoma cases, about 78% harbored one or more of these clustered mutation events, compared to only about 8% of conventional cutaneous melanomas.27PubMed Central. The genetic evolution of acral melanoma
NF1 mutations, one of the four major molecular subtypes mentioned earlier, add another wrinkle. Loss of NF1 function activates some of the same downstream growth signals as BRAF mutations, but through a different mechanism. NF1 loss is not always mutually exclusive with other mutations; it can co-occur with RAS alterations, creating tumors with multiple drivers stacked on top of each other.28PubMed Central. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence This genetic complexity in non-UV subtypes helps explain why a single targeted drug rarely controls the disease for long and why melanoma research increasingly focuses on understanding the tumor’s full molecular profile rather than treating all melanomas as one disease.